Radius Health Reports Second Quarter 2016 Financial and Operating Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Radius Health Reports Second Quarter 2016 Financial and Operating Results

Maxim Group Downgrades Radius Health (RDUS) to Sell

August 4, 2016 2:15 PM EDT

Maxim Group downgraded Radius Health (NASDAQ: RDUS) from Hold to Sell with a price target of $24.00.

Analyst Jason McCarthy commented:

RDUS is "back" to an overvalued state. As such we are downgrading to Sell, from Hold. While we continue to believe that Abaloparatide-SC (and eventually the transdermal patch) will likely gain approval in 2017 in both the U.S. (PDUFA March 30, 2017) and Europe (EMA opinion early 2017), we believe significant challenges lay ahead in penetrating a mature Forteo Market, competition from Biosimilar Forteo in 2018 (from Teva [TEVA-$53.57-Buy]) and patients opting for alternative... More

Radius Health (RDUS) Misses Q2 EPS by 6c

August 4, 2016 6:44 AM EDT

Radius Health (NASDAQ: RDUS) reported Q2 EPS of ($1.01), $0.06 worse than the analyst estimate of ($0.95).

For earnings history and earnings-related data on Radius Health (RDUS) click here.

... More